Clinical trials referenced in this document:
Documents that mention this clinical trial
An update on emerging drugs in osteosarcoma: towards tailored therapies?
Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study
Funding for this research was provided by:
Agence Nationale de la Recherche (RHU CONDOR)
MSD France (PEMBROSARC)
Institut National Du Cancer (PEMBROSARC)
Ministère des Affaires Sociales et de la Santé (PEMBROSARC)
Received: 31 August 2022
Accepted: 19 October 2022
First Online: 27 October 2022
: This study was approved by the Comité de Protection des Personnes (CPP) Sud-Ouest et Outre Mer III (Bordeaux, France) according to good clinical practices and applicable laws and regulations. All methods were performed in accordance with the relevant guidelines and regulations. All patients provided written informed consent.
: The article does not contain any individual person’s data.
: AI: Research grant (AstraZeneca, Bayer, BMS, Merck, MSD, Pharmamar). The other authors declare that they have no competing interests.